There are 10 products in the pipeline for microbial keratitis, an ocular infection...
Neuroptika enrols first patient for dry eye disease trial
Neuroptika has enrolled the first patient in a Phase II clinical trial of NRO-1 for the treatment of dry eye disease.
Gemini Therapeutics starts patient enrolment for AMD study
Gemini Therapeutics has commenced patient enrolment in its Phase I study of GEM103 for the treatment of dry age-related macular degeneration (AMD).
Aldeyra Therapeutics enrols first patient in Phase III GUARD study
Aldeyra Therapeutics has started enrolling patients in the Phase III GUARD clinical trial of ADX-2191 to prevent proliferative vitreoretinopathy (PVR), a rare retinal disease.
ProQR doses first patient in Aurora trial of retinal disease therapy
ProQR Therapeutics has dosed the first patient in a Phase I/II Aurora clinical trial to evaluate QR-1123 in patients with autosomal dominant retinitis pigmentosa (adRP).
Biogen completes enrolment in STAR trial of timrepigene emparvovec
Biogen has completed enrolment in the Phase III STAR clinical trial of timrepigene emparvovec (BIIB111/AAV2-REP1) to treat choroideremia (CHM), a rare, degenerative, X-linked retinal disorder.
Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)
Beovu® (brolucizumab) is an anti-vascular endothelial growth factor (anti-VEGF) drug indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Aerie’s netarsudil shows promise in Phase II trial in Japan
Aerie Pharmaceuticals has reported positive top-line results from the Phase II clinical trial of netarsudil ophthalmic solution conducted in open-angle glaucoma or ocular hypertension patients in Japan.
Aurinia starts voclosporin dosing in Phase II/III study
Aurinia Pharmaceuticals has started dosing patients in a Phase II/III clinical trial of voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
IVERIC bio reports positive results for Zimura in dry AMD trial
IVERIC bio has reported positive initial results from an ongoing Phase IIb clinical trial of Zimura (avacincaptad pegol) in patients suffering from dry age-related macular degeneration (AMD).
ONL Therapeutics trials ONL1204 to treat retinal detachment
Biopharmaceutical company ONL Therapeutics has commenced a Phase I clinical trial to assess its investigational drug, ONL1204, for the treatment of macula-off rhegmatogenous retinal detachment (RRD).